Jasper Therapeutics appoints Ronald Martell as CEO effective March 15, 2022

Jasper Therapeutics, Inc.

Ronald Martell appointed President and CEO, effective March 15, 2022; William Lis transitions to non-executive Chairperson.
Martell receives $675,000 annual salary, 50% bonus target, and option to purchase 4.5% of outstanding shares vesting over 4 years.
Additional 'True-Up Option' for 1.0% of shares granted if Jasper closes equity financing ≥$50 million after start date.
Martell brings 30+ years biotech experience including CEO roles at MorphImmune, Nuvelution, and Achieve Life Sciences.
If terminated without cause or for good reason, Martell receives 18 months base salary subject to release.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ronald Martell

President and Chief Executive Officer

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-15
Filed: February 28, 2022, 6:59 PM ET

appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.

Role change

William Lis

non-executive Chairperson

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-15
Successor: Ronald Martell
Filed: February 28, 2022, 6:59 PM ET

William Lis, who is serving as President, Chief Executive Officer and Executive Chairman of the Board, will become the non-executive Chairperson of the Board.

Appointed

Ronald Martell

Class III director

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-15
Filed: February 28, 2022, 6:59 PM ET

appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William Lis changed role as non-executive Chairperson at Jasper Therapeutics, Inc..

Action: will become
Role: non-executive Chairperson

Exact text from the filing

William Lis, who is serving as President, Chief Executive Officer and Executive Chairman of the Board, will become the non-executive Chairperson of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Martell was appointed as Class III director at Jasper Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-009585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.